

Christopher J D Wallis,, Frcsc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5262842/publications.pdf>

Version: 2024-02-01

157
papers

3,186
citations

186254

28
h-index

182417

51
g-index

160
all docs

160
docs citations

160
times ranked

4989
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of postoperative outcomes among patients treated by male and female surgeons: a population based matched cohort study. <i>BMJ: British Medical Journal</i> , 2017, 359, j4366.	2.3	391
2	Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 21-30.	1.9	222
3	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	7.1	192
4	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ, The</i> , 2016, 352, i851.	6.0	180
5	Association of Surgeon-Patient Sex Concordance With Postoperative Outcomes. <i>JAMA Surgery</i> , 2022, 157, 146.	4.3	148
6	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 498-506.	11.4	126
7	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	1.9	110
8	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 73, 834-844.	1.9	86
9	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. <i>BJU International</i> , 2018, 121, 684-698.	2.5	79
10	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. <i>European Urology</i> , 2018, 73, 11-20.	1.9	76
11	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 708-715.	5.4	64
12	MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence. <i>Prostate</i> , 2016, 76, 869-884.	2.3	58
13	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.	1.9	51
14	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. <i>European Urology Oncology</i> , 2019, 2, 365-378.	5.4	47
15	Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, 50.	7.1	45
16	A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. <i>Journal of Urology</i> , 2016, 196, 361-366.	0.4	44
17	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093.	0.4	44
18	Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matched-cohort study of patients with incident solid-organ malignancies. <i>Cancer</i> , 2019, 125, 2886-2895.	4.1	43

#	ARTICLE	IF	CITATIONS
19	The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies. <i>British Journal of Cancer</i> , 2019, 120, 840-847.	6.4	41
20	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
21	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1260.	7.4	35
22	Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twittersverse in 2019. <i>BJU International</i> , 2020, 125, 173-181.	2.5	35
23	Complications After Radical Prostatectomy or Radiotherapy for Prostate Cancer: Results of a Population-based, Propensity Score-matched Analysis. <i>Urology</i> , 2015, 85, 621-628.	1.0	34
24	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	1.9	33
25	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. <i>Journal of Cancer</i> , 2015, 6, 1160-1171.	2.5	32
26	MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. <i>Oncotarget</i> , 2018, 9, 19159-19176.	1.8	32
27	The Association Between Vasectomy and Prostate Cancer. <i>JAMA Internal Medicine</i> , 2017, 177, 1273.	5.1	31
28	Establishing the Effectiveness of Procedural Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2421.	7.4	31
29	Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 206-212.e1.	1.9	28
30	MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. <i>Prostate</i> , 2019, 79, 1435-1451.	2.3	28
31	The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. <i>Cancer</i> , 2019, 125, 1050-1059.	4.1	28
32	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018, 1, 238-241.	5.4	25
33	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. <i>Urology</i> , 2016, 97, 145-152.	1.0	24
34	Occurrence of and Risk Factors for Urological Intervention During Benign Hysterectomy: Analysis of the National Surgical Quality Improvement Program Database. <i>Urology</i> , 2016, 97, 66-72.	1.0	24
35	Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3571-3581.	2.0	23
36	Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. <i>Urology</i> , 2016, 95, 95-102.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Role of mpMRI of the prostate in screening for prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 464-471.	1.4	22
38	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. <i>Journal of Urology</i> , 2018, 199, 906-914.	0.4	22
39	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology Oncology</i> , 2022, 5, 494-502.	5.4	21
40	Platelet to white blood cell ratio predicts 30-day postoperative infectious complications in patients undergoing radical nephrectomy for renal malignancy. <i>Canadian Urological Association Journal</i> , 2017, 11, E414-20.	0.6	20
41	Effect of radical prostatectomy surgeon volume on complication rates from a large population-based cohort. <i>Canadian Urological Association Journal</i> , 2016, 10, 45.	0.6	19
42	Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 5027-5034.	1.1	17
43	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. <i>PLoS ONE</i> , 2019, 14, e0216255.	2.5	17
44	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab082.	2.9	17
45	Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?. <i>European Urology</i> , 2021, 80, 127-128.	1.9	17
46	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , 2016, 69, 933-941.	1.9	16
47	Desmopressin and the risk of hyponatremia: A population-based cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002930.	8.4	16
48	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e241-e252.	3.8	16
49	Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. <i>Cancer</i> , 2021, 127, 709-719.	4.1	16
50	A Population-Based Assessment of Urologic Procedures and Operations After Surgery or Pelvic Radiation for Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 989-995.	2.5	14
51	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25.	1.6	14
52	Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study. <i>Cancer</i> , 2021, 127, 3156-3162.	4.1	13
53	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. <i>British Journal of Cancer</i> , 2018, 118, 1399-1405.	6.4	12
54	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 800-809.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Prostate Cancer Genetics: A Review. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2015, 26, 79-91.	0.7	12
56	Association Between Primary Local Treatment and Nonmetastatic Prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer. <i>Urology</i> , 2018, 114, 147-154.	1.0	11
57	Assessing patient risk from cancer and COVID-19: Managing patient distress. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 243-246.	1.6	11
58	The cost of intraoperative adverse events in abdominal and pelvic surgery: A systematic review. <i>American Journal of Surgery</i> , 2018, 215, 163-170.	1.8	10
59	Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. <i>European Urology</i> , 2019, 75, 3-7.	1.9	10
60	Perioperative venous thromboembolism prophylaxis in prostate cancer surgery. <i>World Journal of Urology</i> , 2020, 38, 593-600.	2.2	10
61	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554.	2.2	10
62	Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. <i>Cancers</i> , 2021, 13, 2844.	3.7	10
63	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. <i>Journal of Urology</i> , 2022, 207, 1029-1037.	0.4	9
64	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>Urology</i> , 2016, 96, 142-147.	1.0	8
65	Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 2581-2582.	27.0	8
66	Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer—The Forgotten Dance Partner?. <i>JAMA Oncology</i> , 2019, 5, 144.	7.1	8
67	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. <i>Urology</i> , 2021, 155, 117-123.	1.0	7
68	Estimating the effect of immortal-time bias in urological research: a case example of testosterone replacement therapy. <i>BJU International</i> , 2017, 120, 584-590.	2.5	6
69	Peripheral Nerve Injury during Abdominal-Pelvic Surgery: Analysis of the National Surgical Quality Improvement Program Database. <i>American Surgeon</i> , 2017, 83, 1214-1219.	0.8	6
70	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. <i>Urology</i> , 2018, 113, 138-145.	1.0	6
71	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality—a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 622-629.	3.9	6
72	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. <i>Cancer Causes and Control</i> , 2021, 32, 675-680.	1.8	6

#	ARTICLE	IF	CITATIONS
73	Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 192.e1-192.e9.	1.6	6
74	Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 74-79.	3.9	6
75	Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence. <i>Canadian Urological Association Journal</i> , 2016, 10, 277.	0.6	5
76	â€œProtecTionâ€™™ from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?. <i>BJU International</i> , 2017, 119, 513-514.	2.5	5
77	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients â€œ A Cross Sectional Study. <i>Urology</i> , 2019, 134, 154-162.	1.0	5
78	Seeking the Truth: Understanding the Impact of Missing Data on the Validity of the New Surveillance, Epidemiology and End Results Prostate with Watchful Waiting Database. <i>European Urology</i> , 2020, 78, 345-346.	1.9	5
79	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	1.0	5
80	Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	5
81	Women as Authors of Randomized Controlled Trials of Minimally Invasive Surgery: Systematic Review and Meta-Analysis of 3 Decades of Trials. <i>Journal of the American College of Surgeons</i> , 2021, 233, 167-175e9.	0.5	5
82	Medicare Two-Midnight Rule Accelerated Shift To Observation Stays. <i>Health Affairs</i> , 2021, 40, 1688-1696.	5.2	5
83	Comments on Surgeon-Patient Sex Concordance and Postoperative Outcomesâ€™Reply. <i>JAMA Surgery</i> , 2022, 157, 639.	4.3	5
84	Systematic review of hematuria and acute renal failure with tranexamic acid. <i>European Journal of Haematology</i> , 2022, 108, 510-517.	2.2	5
85	Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis. <i>MDM Policy and Practice</i> , 2017, 2, 238146831770947.	0.9	4
86	Radical cystectomy in patients with disseminated disease: An assessment of perioperative outcomes using the National Surgical Quality Improvement Program database. <i>Canadian Urological Association Journal</i> , 2017, 11, 244-8.	0.6	4
87	â€œReverse Stage Migrationâ€™: What Can Population-based Data Tell Us About Trends in Prostate Cancer Presentation?. <i>European Urology Oncology</i> , 2018, 1, 321-322.	5.4	4
88	The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, E236-E248.	0.6	4
89	Links between age and sex of surgeons and patientsâ€™™ outcomes. <i>BMJ: British Medical Journal</i> , 2018, 361, k1691.	2.3	4
90	Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. <i>European Urology Focus</i> , 2021, 7, 489-496.	3.1	4

#	ARTICLE	IF	CITATIONS
91	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2110950.	5.9	4
92	Trends in medicare spending across strata of resource utilization among older individuals in the United States. EClinicalMedicine, 2021, 36, 100873.	7.1	4
93	Out-of-pocket costs for commercially insured patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 797-805.	1.6	4
94	Dissecting the role of radical cystectomy and urinary diversion in post-operative complications: an analysis using the American College of Surgeons national surgical quality improvement program database. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 1006-1019.	1.5	4
95	Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. Cancer Medicine, 2022, 11, 4273-4282.	2.8	4
96	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	4
97	Risk factors "you find what you are looking for. Nature Reviews Urology, 2017, 14, 202-204.	3.8	3
98	Postoperative Radiotherapy in Locally Advanced Prostate Cancer: A Question of Who and When. European Urology, 2017, 71, 894-895.	1.9	3
99	Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 241.e1-241.e6.	1.6	3
100	Survival and peri-operative outcomes among patients with rectal cancer: the role of prior radiotherapy due to prostate cancer. International Journal of Colorectal Disease, 2019, 34, 97-104.	2.2	3
101	Re-operation within 30 days of radical cystectomy: Identifying high-risk patients and complications using ACS-NSQIP database. Canadian Urological Association Journal, 2020, 15, E1-E5.	0.6	3
102	Is there an association between a history of military service and cancer diagnosis? Results from a US national-level study of self-reported outcomes. Cancer Causes and Control, 2021, 32, 47-55.	1.8	3
103	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 64.e17-64.e24.	1.6	3
104	Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. BJUI Compass, 2022, 3, 383-391.	1.3	3
105	Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice of general practitioners and cardiologists in Victoria, BC. Canadian Urological Association Journal, 2014, 8, 30.	0.6	2
106	Variation in clinical practice: forests and trees revisited. Nature Reviews Urology, 2017, 14, 511-512.	3.8	2
107	Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada. BMJ Open, 2019, 9, e032170.	1.9	2
108	Addressing Mental Health in Urology Patients: The Time is Now. European Urology Focus, 2020, 6, 1137-1139.	3.1	2

#	ARTICLE	IF	CITATIONS
109	Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomes. <i>International Journal of Urology</i> , 2020, 27, 711-718.	1.0	2
110	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. <i>BJU International</i> , 2021, 127, 654-664.	2.5	2
111	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 21.	1.6	2
112	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 238-247.	3.9	2
113	Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 61.e21-61.e28.	1.6	2
114	Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 288-288.	1.6	2
115	Local therapy in patients with metastatic prostate cancer: a new standard of care?. <i>Translational Cancer Research</i> , 2019, 8, S592-S594.	1.0	2
116	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 131-131.	1.6	2
117	Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 244-251.	1.9	2
118	Have we mis-PRONOUNCED the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 657-658.	3.9	2
119	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. <i>Future Oncology</i> , 2022, 18, 2771-2781.	2.4	2
120	Isolated brain metastasis from a small renal mass. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216081.	0.5	1
121	Reply from Authors re: Martin Spahn, Alan Dal Pra, Daniel Aebersold, Bertrand Tombal. Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. <i>Eur Urol</i> 2016;70:31-2. <i>European Urology</i> , 2016, 70, 33-34.	1.9	1
122	The utility of microRNA as biomarkers in predicting progression and survival in patients with clear cell renal cell carcinoma. <i>BJU International</i> , 2017, 120, 305-307.	2.5	1
123	RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	1
124	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. <i>Canadian Urological Association Journal</i> , 2017, 12, E59-63.	0.6	1
125	Selecting patients for prostate cancer treatment: the role of comorbidity. <i>BJU International</i> , 2018, 121, 164-165.	2.5	1
126	Reply to Comment on: "The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies". <i>British Journal of Cancer</i> , 2019, 121, 195-196.	6.4	1

#	ARTICLE	IF	CITATIONS
127	Re: Comparison of Population-based Observational Studies with Randomized Trials in Oncology. <i>European Urology</i> , 2019, 76, 869-870.	1.9	1
128	Adjuvant Versus Salvage Radiotherapy Following Radical Prostatectomy: Meta-analysis of the Effect of Comparator Salvage Approach on Study Conclusions. <i>European Urology</i> , 2020, 77, 395-396.	1.9	1
129	Elevated suicide risk among patients with urologic malignancies: highlighting at-risk populations. <i>Annals of Translational Medicine</i> , 2020, 8, 272-272.	1.7	1
130	Real-world utilization of docetaxel among men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.. <i>Journal of Clinical Oncology</i> , 2021, 39, 47-47.	1.6	1
131	Use of psychotropic drugs among older patients with bladder cancer in the United States. <i>Psycho-Oncology</i> , 2021, 30, 832-843.	2.3	1
132	Geographic variation in systemic therapy in men age 66 years and older with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.. <i>Journal of Clinical Oncology</i> , 2021, 39, 50-50.	1.6	1
133	Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 2636-2644.	2.8	1
134	Stress Incontinence Surgery Does Not Cause Pelvic Malignancy: A Population-Based Cohort Study. <i>Journal of Urology</i> , 2021, 205, 1725-1732.	0.4	1
135	Mental health screening and diagnosis in cancer patients: Impact on mortality and suggestion of racial bias. <i>Cancer</i> , 2022, 128, 234-236.	4.1	1
136	Reply. <i>Urology</i> , 2015, 85, 628.	1.0	0
137	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 1067-1068.	0.4	0
138	RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>Eur J Cancer</i> . 2017 Oct; 84:88-101. <i>European Journal of Cancer</i> , 2018, 94, 216-217.	2.8	0
139	Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2017.10.002 . <i>European Urology</i> , 2018, 73, e51.	1.9	0
140	Decreasing incidence of venous thromboembolic events after radical cystectomy: are we finally improving?. <i>Translational Andrology and Urology</i> , 2018, 7, S747-S750.	1.4	0
141	Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2021, 37, 285-286.	1.9	0
142	EDITORIAL COMMENT. <i>Urology</i> , 2021, 147, 160-161.	1.0	0
143	Absence of a positive outcome bias in randomized controlled trials of minimally invasive surgical techniques. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 163-165.	5.0	0
144	Transparency of racial participation reporting in randomized controlled trials of minimally invasive surgical techniques. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 2600-2606.	2.4	0

#	ARTICLE	IF	CITATIONS
145	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 56.e1-56.e1.	1.6	0
146	Not So "Active" Surveillance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 716-717.	0.8	0
147	Editorial Comment. <i>Journal of Urology</i> , 2021, 206, 1211.	0.4	0
148	Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 252-252.	1.6	0
149	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22144-e22144.	1.6	0
150	Androgen deprivation therapy and Gleason grade: unravelling implications on survival. <i>Translational Cancer Research</i> , 2019, 8, 729-731.	1.0	0
151	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 758-759.	0.4	0
152	Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9552-9552.	1.6	0
153	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 1093-1093.	0.4	0
154	Comment on "Responsibilities and Expectations: Considerations of Disclosure of Overlapping Operations" <i>Annals of Surgery</i> , 2021, 274, e725-e726.	4.2	0
155	Re: Long-term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-based Cohort Study. <i>European Urology</i> , 2021, 81, 119-119.	1.9	0
156	Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2022, 40, 53-53.	1.6	0
157	Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	3.9	0